{"gene":"RGS20","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1998,"finding":"RGSZ1 (RGS20) is a Gz-selective GTPase-activating protein (GAP) that accelerates hydrolysis of Gαz-GTP over 400-fold with Km ~2 nM, shows 100-fold selectivity for Gαz over Gαi, and when co-reconstituted into phospholipid vesicles with Gz and m2 muscarinic receptors increased agonist-stimulated GTPase >15-fold. RGSZ1 is tightly membrane-bound in brain and its regulatory activity depends on stable bilayer association.","method":"In vitro GTPase assay with purified recombinant protein, phospholipid vesicle reconstitution, membrane fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified components, multiple orthogonal assays, replicated across two simultaneous papers (PMIDs 9748280 and 9748279)","pmids":["9748280"],"is_preprint":false},{"year":1998,"finding":"Phosphorylation of Gαz by protein kinase C (PKC) inhibits the GAP activity of RGSZ1 (RGS20) toward Gαz-GTP, providing a mechanism for potentiation of Gz signaling by PKC.","method":"In vitro GTPase assay using PKC-phosphorylated Gαz and purified recombinant RGSZ1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic assay with defined substrates, independently reported in two simultaneous papers (PMIDs 9748280 and 9748279)","pmids":["9748280","9748279"],"is_preprint":false},{"year":1998,"finding":"RGSZ1 (RGS20) was identified via yeast two-hybrid as a binding partner for constitutively active Gαz, confirming selective interaction with Gαz over other Gαi family members.","method":"Yeast two-hybrid screen, biochemical GAP assay with recombinant protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — yeast two-hybrid plus in vitro enzymatic validation, replicated across two independent labs in the same year","pmids":["9748279"],"is_preprint":false},{"year":2001,"finding":"RGSZ1 and Ret RGS are splice variants of a single gene, RGS20, which spans ~107 kb and contains at least seven exons. Multiple translational start sites within the RGSZ1 ORF may explain molecular weight heterogeneity of purified brain RGSZ protein.","method":"Genomic cloning, exon mapping, RT-PCR, Northern blot","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genomic characterization establishing gene structure, replicated across multiple tissue types","pmids":["11735229"],"is_preprint":false},{"year":2002,"finding":"RGSZ1 (RGS20) interacts with Gαi subunits (not only Gαz) in an AlF4−-dependent manner and accelerates intrinsic GTPase activity of Gαi1. In PC12 cells, RGSZ1 blocks MAPK activity induced by α2-adrenergic receptor agonist, and attenuates D2 dopamine receptor agonist-induced SRE reporter activity in CHO cells.","method":"GST pull-down, co-immunoprecipitation, yeast two-hybrid with luciferase reporter, single-turnover GTPase assay, yeast pheromone response assay, MAPK assay, SRE reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (pull-down, co-IP, yeast two-hybrid, in vitro GTPase, functional cell assays) in a single study","pmids":["12379657"],"is_preprint":false},{"year":2002,"finding":"RGSZ1 (RGS20) directly interacts with SCG10 (a microtubule-destabilizing protein) via yeast two-hybrid and direct binding assays. Upon NGF treatment, GFP-tagged RGSZ1 translocates to the Golgi complex in PC12 cells where SCG10 is also distributed. Binding of RGSZ1 to SCG10 blocks SCG10-induced microtubule disassembly in vitro.","method":"Yeast two-hybrid, direct binding assay, GFP live-cell imaging/subcellular localization, turbidimetric and microscopy-based in vitro microtubule polymerization assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods including in vitro functional reconstitution and live-cell imaging with functional consequence","pmids":["11882662"],"is_preprint":false},{"year":2004,"finding":"Knockdown of RGSZ1 (RGS20) with antisense oligodeoxynucleotides in mouse CNS significantly increased supraspinal antinociception by morphine, heroin, DAMGO, and endomorphin-1 (but not endomorphin-2), and extended morphine analgesia duration, while having no effect on delta opioid receptor agonists DPDPE and deltorphin II. RGSZ1 knockdown facilitated morphine tolerance development.","method":"Antisense oligodeoxynucleotide knockdown in vivo, antinociception behavioral assay","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vivo knockdown with specific behavioral phenotype, but single lab, single primary method","pmids":["14997173"],"is_preprint":false},{"year":2006,"finding":"RGSZ1 (RGS20) interacts with PKCI-1 via its N-terminal cysteine string region (shared with RZ subfamily), confirmed by co-immunoprecipitation and immunofluorescence. RGSZ1 and PKCI-1 together significantly reduce mu opioid receptor-mediated inhibition of cAMP more than RGSZ1 alone. 14-3-3 inhibits PKC-mediated phosphorylation of Gαz, and RGSZ1 competes with PKCI-1 for 14-3-3 binding.","method":"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence, cAMP functional assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — yeast two-hybrid plus co-IP plus functional cAMP assay, single lab","pmids":["17126529"],"is_preprint":false},{"year":2008,"finding":"Activated Gαo and Gαi2 (but not Gαq, Gαi1, or Gαi3) interact with RGS20 and promote its proteasomal degradation via ubiquitination. Serotonin-1A receptor activation reduces RGS20 levels through this Gαo/i-proteasomal mechanism. Loss of RGS20 via this pathway reduces RGS20-mediated attenuation of Gi inhibition of β-adrenergic receptor-induced cAMP, enabling cross-pathway signal integration.","method":"Co-immunoprecipitation, proteasomal inhibitor (lactacystin, MG132) rescue experiments, ubiquitination assay, cAMP functional assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional and biochemical assays in single lab, multiple orthogonal methods","pmids":["18407463"],"is_preprint":false},{"year":2010,"finding":"RGS20 forms a ternary pre-associated complex with the melatonin MT1 receptor dimer and Gi protein. BRET analysis with probes at multiple sites revealed an asymmetric architecture in which one Gi and one RGS20 bind to separate protomers of the MT1 dimer; this complex rearranges upon agonist activation. Validated with MT1/MT2 heterodimers.","method":"Bioluminescence resonance energy transfer (BRET) with multi-site probe insertion, validated with heterodimers","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — BRET with multiple probe positions providing structural constraints, cross-validated with receptor heterodimers, rigorous single study","pmids":["20859254"],"is_preprint":false},{"year":2012,"finding":"Estradiol benzoate treatment increases a 55 kDa membrane-associated RGSZ1 (RGS20) protein in the paraventricular nucleus of the hypothalamus and other brain regions, associated with partial desensitization of 5-HT1A receptor signaling as measured by reduced oxytocin and ACTH release.","method":"Western blotting, subcellular fractionation, in vivo hormone release assay","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — biochemical fractionation with in vivo functional readout, single lab","pmids":["22251927"],"is_preprint":false},{"year":2014,"finding":"GPER1 stimulation alters post-translational modifications of RGSz1 (RGS20): high-molecular-weight RGSz1 isoforms are SUMOylated and glycosylated, localize to detergent-resistant membrane microdomains (DRM), and are increased by estradiol and G-1 treatment. Activated Gαz also localizes to DRM, so increased DRM-localized RGSz1 is proposed to reduce Gαz activity and functionally uncouple 5-HT1AR signaling.","method":"Subcellular fractionation (DRM isolation), immunoblotting for SUMOylation/glycosylation/phosphorylation, in vivo hormone release functional assay","journal":"Neuroendocrinology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — biochemical fractionation plus PTM characterization with in vivo functional readout, single lab","pmids":["25402859"],"is_preprint":false},{"year":2018,"finding":"Chronic morphine administration promotes RGSz1 (RGS20) activity in the periaqueductal gray (PAG), which modulates Wnt/β-catenin transcriptional signaling to promote analgesic tolerance. Suppression of RGSz1 stabilizes Axin2-Gαz complexes near the membrane and promotes β-catenin activation, delaying morphine tolerance.","method":"Genetic mouse models (global and brain region-targeted RGSz1 knockout/knockdown), biochemical assays, next-generation RNA sequencing, viral vector delivery","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models with region-specific manipulation, biochemical pathway analysis, transcriptomics, replicated across sex","pmids":["29440403"],"is_preprint":false},{"year":2022,"finding":"RGS20 interacts physically with the PI3K p85α subunit in penile cancer cell lines and regulates PI3K/AKT signaling activation. Knockdown of PI3K p85α or p110α phenocopies RGS20 depletion, while expression of constitutively active PI3K p110α rescues proliferation and migration defects caused by RGS20 depletion.","method":"Co-immunoprecipitation, siRNA knockdown, constitutively active PI3K overexpression rescue, xenograft tumor model","journal":"Journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — co-IP plus epistasis via rescue experiment, in vitro and in vivo, single lab","pmids":["35498542"],"is_preprint":false},{"year":2022,"finding":"RGSz1 (RGS20) in vlPAG projections to the VTA modulates morphine reward. BRET sensor experiments demonstrate RGSz1 selectively modulates Gαz (but not other Gαi family subunits) and impedes MOPR-mediated Gαz signaling; RGSz1 KO enhances opioid-induced cAMP inhibition in PAG membranes.","method":"Cre-dependent viral vector knockdown in specific brain circuits, conditioned place preference assay, BRET sensors, cAMP inhibition assay in PAG membranes","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — circuit-specific genetic manipulation plus BRET-based biochemical selectivity assay plus functional cAMP readout, multiple orthogonal approaches","pmids":["36310031"],"is_preprint":false},{"year":2023,"finding":"RGS20 is palmitoylated, and a conserved cysteine residue in the RGS domain is a critical palmitoylation site. Palmitoylation increases RGS20 association with active Gαo but does not affect GAP activity per se; however, palmitoylation increases inhibition of Gαo-mediated cAMP signaling, indicating a non-GAP mechanism of Gαo regulation by RGS20.","method":"Palmitoylation assay, site-directed mutagenesis of cysteine residues, co-immunoprecipitation with active Gαo, cAMP functional assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis plus biochemical binding plus functional cAMP assay, single lab","pmids":["37075876"],"is_preprint":false},{"year":2024,"finding":"SP1 undergoes phase separation and activates RGS20 transcription through super-enhancer (SE) mechanisms. CUT&RUN identified RGS20 as the top SP1/H3K27ac SE target in lung adenocarcinoma; SP1 zinc finger 3 in the DNA-binding domain is essential for phase separation. The demethylase inhibitor GSK-J4 abolishes SP1 phase separation and RGS20 activation.","method":"CUT&RUN (SP1 and H3K27ac), phase separation assay, domain deletion mutagenesis, GSK-J4 inhibitor treatment, reporter assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CUT&RUN plus functional phase separation assay plus mutagenesis, single lab","pmids":["38976739"],"is_preprint":false},{"year":2024,"finding":"RGS20 promotes NSCLC cell proliferation by inhibiting PKA-Hippo signaling, reducing YAP phosphorylation and facilitating its nuclear translocation, and by activating autophagy. Forskolin (a GPCR/PKA activator) increased YAP phosphorylation and reversed the proliferative effect of RGS20 overexpression.","method":"Transcriptome sequencing, immunofluorescence for YAP nuclear translocation, Western blotting, Hippo pathway inhibitor (GA-017), PKA activator (forskolin) rescue, in vivo xenograft","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — transcriptomics plus imaging plus pharmacological rescue in vitro and in vivo, single lab","pmids":["38431606"],"is_preprint":false},{"year":2025,"finding":"RGS20 inhibition in glioma cells intrinsically activates WNT/β-catenin signaling in a ligand-independent manner, enhancing tumor sphere formation, upregulating stem cell markers, and promoting temozolomide resistance. This mechanism operates in hypoxic niches where β-catenin signaling is enriched with low RGS20 expression.","method":"In vitro sphere formation, stem cell marker expression, in vivo tumor model, human glioblastoma specimen analysis, RGS20 knockdown/overexpression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — loss-of-function with specific pathway and phenotypic readout in vitro and in vivo, single lab, no biochemical mechanism of how RGS20 inhibits β-catenin established","pmids":["41315804"],"is_preprint":false}],"current_model":"RGS20 (RGSZ1/ZGAP1) is a member of the RZ subfamily of RGS proteins that primarily functions as a highly selective GTPase-activating protein (GAP) for Gαz (and to a lesser extent Gαi/o), accelerating Gαz-GTP hydrolysis >400-fold; its activity is regulated by PKC-mediated phosphorylation of Gαz (which inhibits GAP activity), by palmitoylation of a conserved RGS-domain cysteine (which enhances Gαo association and inhibition independent of GAP activity), and by Gαo/i-stimulated ubiquitination and proteasomal degradation; it localizes to membranes and Golgi through a cysteine string motif and interacts with partners including PKCI-1, SCG10/stathmin (blocking microtubule disassembly), and the PI3K p85α subunit; within GPCR signaling complexes it occupies a distinct protomer of receptor dimers (e.g., MT1) from the coupled G protein; in the brain it modulates mu opioid receptor signaling and morphine tolerance via Gαz/Wnt/β-catenin cross-talk in the periaqueductal gray, and in cancer contexts it regulates PI3K/AKT and PKA-Hippo-YAP pathways and WNT/β-catenin signaling."},"narrative":{"mechanistic_narrative":"RGS20 (RGSZ1) is a membrane-bound GTPase-activating protein of the RZ subfamily of RGS proteins that functions as a highly selective negative regulator of Gz-coupled G protein signaling [PMID:9748280, PMID:9748279]. It accelerates hydrolysis of Gαz-GTP over 400-fold with ~100-fold selectivity for Gαz over Gαi, and its regulatory activity depends on stable bilayer association [PMID:9748280]; RGSZ1 and Ret RGS arise as splice variants of the single RGS20 gene [PMID:11735229]. Although Gz-selective, RGS20 also engages Gαi subunits in an activation-dependent manner and dampens receptor-driven MAPK and SRE signaling [PMID:12379657]. RGS20 activity is tuned by multiple inputs: PKC phosphorylation of Gαz inhibits its GAP activity [PMID:9748280, PMID:9748279], palmitoylation of a conserved RGS-domain cysteine enhances association with active Gαo and inhibition of Gαo-cAMP signaling through a non-GAP mechanism [PMID:37075876], and activated Gαo/Gαi2 promote RGS20 ubiquitination and proteasomal degradation, allowing receptor-driven cross-pathway signal integration [PMID:18407463]. Within GPCR complexes, RGS20 pre-associates with melatonin MT1 receptor dimers and Gi in an asymmetric architecture, occupying a separate protomer from the coupled G protein [PMID:20859254]. In the CNS, RGS20 constrains mu opioid receptor signaling and morphine antinociception, and chronic morphine drives RGSz1 activity in the periaqueductal gray to promote analgesic tolerance via Gαz/Axin2/Wnt–β-catenin cross-talk, while circuit-specific RGSz1 in vlPAG-to-VTA projections modulates opioid reward [PMID:14997173, PMID:29440403, PMID:36310031]. In cancer, RGS20 acts as a proliferative driver through physical interaction with the PI3K p85α subunit and PI3K/AKT activation [PMID:35498542], inhibition of PKA-Hippo signaling to promote YAP nuclear translocation [PMID:38431606], and ligand-independent WNT/β-catenin activation supporting tumor stemness and drug resistance [PMID:41315804]; its transcription is driven by SP1 super-enhancer phase separation [PMID:38976739]. RGS20 additionally binds the microtubule-destabilizing protein SCG10 and blocks SCG10-induced microtubule disassembly [PMID:11882662].","teleology":[{"year":1998,"claim":"Established the core biochemical identity of RGS20 as a Gz-selective GAP, answering what molecular activity this protein carries and on which G protein it acts.","evidence":"In vitro GTPase assays with purified protein, phospholipid vesicle reconstitution with Gz and m2 receptors, and yeast two-hybrid against constitutively active Gαz","pmids":["9748280","9748279"],"confidence":"High","gaps":["Did not define structural basis of Gαz selectivity","Cellular regulatory inputs not yet identified"]},{"year":1998,"claim":"Identified the first regulatory input on RGS20 GAP activity, showing PKC phosphorylation of the Gαz substrate inhibits GAP function and thereby potentiates Gz signaling.","evidence":"In vitro GTPase assay using PKC-phosphorylated Gαz and purified recombinant RGSZ1","pmids":["9748280","9748279"],"confidence":"High","gaps":["Phosphorylation acts on substrate, not RGS20 directly","In vivo relevance of this regulation not tested"]},{"year":2001,"claim":"Resolved the gene architecture, showing RGSZ1 and Ret RGS are splice variants of one RGS20 gene, explaining observed protein heterogeneity.","evidence":"Genomic cloning, exon mapping, RT-PCR and Northern blot across tissues","pmids":["11735229"],"confidence":"High","gaps":["Functional distinction between isoforms not established"]},{"year":2002,"claim":"Broadened the substrate and functional scope by showing RGS20 also acts on Gαi and attenuates receptor-driven MAPK/SRE signaling, and that it binds the microtubule-destabilizing protein SCG10.","evidence":"Pull-down, co-IP, yeast two-hybrid, single-turnover GTPase, cell-based MAPK/SRE reporters, and in vitro microtubule polymerization assays with Golgi localization imaging","pmids":["12379657","11882662"],"confidence":"High","gaps":["Physiological significance of SCG10 binding in neurons not established","Relative contribution of Gi versus Gz regulation in cells unclear"]},{"year":2004,"claim":"Established a physiological role in opioid signaling, showing RGS20 constrains mu opioid receptor-mediated antinociception and modulates tolerance in vivo.","evidence":"Antisense oligodeoxynucleotide knockdown in mouse CNS with antinociception behavioral assays","pmids":["14997173"],"confidence":"Medium","gaps":["Single lab and single knockdown method","Direct biochemical link to Gαz in this context not shown"]},{"year":2006,"claim":"Identified protein partners (PKCI-1, 14-3-3) coupling RGS20 to the PKC/Gαz phosphorylation axis and showed enhanced suppression of MOPR-cAMP signaling.","evidence":"Yeast two-hybrid, co-IP, immunofluorescence, and cAMP functional assays","pmids":["17126529"],"confidence":"Medium","gaps":["Single lab","Stoichiometry and direct structural basis of the competition for 14-3-3 not resolved"]},{"year":2008,"claim":"Defined a feedback degradation mechanism in which activated Gαo/Gαi2 trigger RGS20 ubiquitination and proteasomal turnover, enabling cross-pathway signal integration.","evidence":"Co-IP, proteasome inhibitor rescue, ubiquitination assay, cAMP functional assay","pmids":["18407463"],"confidence":"Medium","gaps":["E3 ligase responsible for ubiquitination not identified","Single lab"]},{"year":2010,"claim":"Provided structural insight into how RGS20 is organized within GPCR complexes, revealing an asymmetric pre-associated MT1 dimer-Gi-RGS20 architecture.","evidence":"BRET with multi-site probe insertion, cross-validated with MT1/MT2 heterodimers","pmids":["20859254"],"confidence":"High","gaps":["No atomic-resolution structure","Generality across other receptor dimers not established"]},{"year":2014,"claim":"Linked hormone/estrogen signaling to RGS20 regulation via post-translational modification and membrane microdomain targeting controlling 5-HT1A receptor signaling.","evidence":"DRM fractionation, immunoblotting for SUMOylation/glycosylation, and in vivo hormone release assays (also building on 2012 estradiol findings)","pmids":["25402859","22251927"],"confidence":"Medium","gaps":["Direct enzymes mediating SUMOylation/glycosylation not identified","Causal link between DRM localization and Gαz inactivation inferred"]},{"year":2018,"claim":"Established the in vivo circuit and transcriptional mechanism by which RGS20 controls morphine tolerance through Gαz/Axin2/Wnt-β-catenin cross-talk in the periaqueductal gray.","evidence":"Global and region-targeted RGSz1 mouse models, biochemical assays, RNA-seq, and viral delivery","pmids":["29440403"],"confidence":"High","gaps":["Molecular basis of Axin2-Gαz complex stabilization incomplete","Direct GAP-versus-scaffold contribution not dissected"]},{"year":2022,"claim":"Extended circuit-level and biochemical selectivity findings, confirming RGSz1 selectively impedes MOPR-mediated Gαz signaling and modulates opioid reward.","evidence":"Cre-dependent circuit-specific viral knockdown, conditioned place preference, BRET sensors, and PAG membrane cAMP assays","pmids":["36310031"],"confidence":"High","gaps":["Downstream effectors in VTA projection not fully mapped"]},{"year":2023,"claim":"Uncovered palmitoylation of a conserved RGS-domain cysteine as a GAP-independent regulatory mechanism enhancing Gαo association and inhibition.","evidence":"Palmitoylation assay, cysteine mutagenesis, co-IP with active Gαo, and cAMP functional assays","pmids":["37075876"],"confidence":"Medium","gaps":["Palmitoyltransferase responsible not identified","Single lab"]},{"year":2024,"claim":"Established RGS20 as a cancer driver and defined its transcriptional control, linking SP1 super-enhancer phase separation to RGS20 expression and RGS20 to PI3K/AKT and PKA-Hippo-YAP signaling.","evidence":"CUT&RUN, phase separation and reporter assays, co-IP with PI3K p85α, epistasis rescue, transcriptomics, and xenograft models (also penile cancer p85α study)","pmids":["38976739","38431606","35498542"],"confidence":"Medium","gaps":["Mechanistic link between RGS20 GAP/G-protein activity and PI3K or Hippo regulation unresolved","Single lab per cancer context"]},{"year":2025,"claim":"Connected RGS20 loss to ligand-independent WNT/β-catenin activation driving glioma stemness and drug resistance in hypoxic niches.","evidence":"Sphere formation, stem marker expression, knockdown/overexpression, in vivo tumor model, and human glioblastoma specimens","pmids":["41315804"],"confidence":"Medium","gaps":["No biochemical mechanism for how RGS20 represses β-catenin established","Single lab"]},{"year":null,"claim":"It remains unresolved how RGS20's defined Gαz/Gαi GAP and palmitoylation-dependent activities mechanistically connect to the PI3K/AKT, PKA-Hippo-YAP, and WNT/β-catenin pathways it controls in cancer, and which E3 ligase and modifying enzymes govern its turnover and PTMs.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of RGS20 in GPCR complexes at atomic resolution","Direct biochemical bridge between G-protein regulation and oncogenic signaling pathways missing","Enzymes mediating ubiquitination, SUMOylation, glycosylation, and palmitoylation unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,4,15]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,11,15]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,8,9]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[6,12,14]}],"complexes":["MT1 receptor dimer–Gi–RGS20 ternary complex"],"partners":["GNAZ","GNAO1","GNAI2","SCG10/STMN2","HINT1/PKCI-1","YWHA/14-3-3","PIK3R1/P85Α","MTNR1A/MT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O76081","full_name":"Regulator of G-protein signaling 20","aliases":["Gz-selective GTPase-activating protein","G(z)GAP","Gz-GAP","Regulator of G-protein signaling Z1","Regulator of Gz-selective protein signaling 1"],"length_aa":388,"mass_kda":43.7,"function":"Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Binds selectively to G(z)-alpha and G(alpha)-i2 subunits, accelerates their GTPase activity and regulates their signaling activities. The G(z)-alpha activity is inhibited by the phosphorylation and palmitoylation of the G-protein. Negatively regulates mu-opioid receptor-mediated activation of the G-proteins (By similarity)","subcellular_location":"Membrane; Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O76081/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RGS20","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RGS20","total_profiled":1310},"omim":[{"mim_id":"607193","title":"REGULATOR OF G PROTEIN SIGNALING 20; RGS20","url":"https://www.omim.org/entry/607193"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":36.6}],"url":"https://www.proteinatlas.org/search/RGS20"},"hgnc":{"alias_symbol":["RGSZ1","ZGAP1"],"prev_symbol":[]},"alphafold":{"accession":"O76081","domains":[{"cath_id":"1.10.167.10","chopping":"252-386","consensus_level":"medium","plddt":96.145,"start":252,"end":386}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76081","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76081-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76081-F1-predicted_aligned_error_v6.png","plddt_mean":61.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RGS20","jax_strain_url":"https://www.jax.org/strain/search?query=RGS20"},"sequence":{"accession":"O76081","fasta_url":"https://rest.uniprot.org/uniprotkb/O76081.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76081/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76081"}},"corpus_meta":[{"pmid":"9748280","id":"PMC_9748280","title":"RGSZ1, a Gz-selective RGS protein in brain. Structure, membrane association, regulation by Galphaz phosphorylation, and relationship to a Gz gtpase-activating protein subfamily.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9748280","citation_count":128,"is_preprint":false},{"pmid":"9748279","id":"PMC_9748279","title":"RGSZ1, a Gz-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of Gzalpha.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9748279","citation_count":108,"is_preprint":false},{"pmid":"29484420","id":"PMC_29484420","title":"lncRNA NEAT1 promotes cell proliferation and invasion by regulating miR‑365/RGS20 in oral squamous cell carcinoma.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29484420","citation_count":63,"is_preprint":false},{"pmid":"20859254","id":"PMC_20859254","title":"Molecular organization and dynamics of the melatonin MT₁ receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20859254","citation_count":57,"is_preprint":false},{"pmid":"17126529","id":"PMC_17126529","title":"RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/17126529","citation_count":52,"is_preprint":false},{"pmid":"14997173","id":"PMC_14997173","title":"RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance.","date":"2004","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14997173","citation_count":49,"is_preprint":false},{"pmid":"12379657","id":"PMC_12379657","title":"Regulator of G protein signaling Z1 (RGSZ1) interacts with Galpha i subunits and regulates Galpha i-mediated cell signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12379657","citation_count":40,"is_preprint":false},{"pmid":"11882662","id":"PMC_11882662","title":"The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11882662","citation_count":32,"is_preprint":false},{"pmid":"11735229","id":"PMC_11735229","title":"RGSZ1 and Ret RGS: two of several splice variants from the gene RGS20.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11735229","citation_count":31,"is_preprint":false},{"pmid":"29440403","id":"PMC_29440403","title":"Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29440403","citation_count":26,"is_preprint":false},{"pmid":"38976739","id":"PMC_38976739","title":"SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38976739","citation_count":22,"is_preprint":false},{"pmid":"25402859","id":"PMC_25402859","title":"GPER1 stimulation alters posttranslational modification of RGSz1 and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus.","date":"2014","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25402859","citation_count":15,"is_preprint":false},{"pmid":"22251927","id":"PMC_22251927","title":"Estradiol induces partial desensitization of serotonin 1A receptor signaling in the paraventricular nucleus of the hypothalamus and alters expression and interaction of RGSZ1 and Gαz.","date":"2012","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22251927","citation_count":14,"is_preprint":false},{"pmid":"35498542","id":"PMC_35498542","title":"RGS20 Promotes Tumor Progression through Modulating PI3K/AKT Signaling Activation in Penile Cancer.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35498542","citation_count":13,"is_preprint":false},{"pmid":"38431606","id":"PMC_38431606","title":"RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway.","date":"2024","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/38431606","citation_count":11,"is_preprint":false},{"pmid":"18407463","id":"PMC_18407463","title":"Galphao/i-stimulated proteosomal degradation of RGS20: a mechanism for temporal integration of Gs and Gi pathways.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18407463","citation_count":11,"is_preprint":false},{"pmid":"36310031","id":"PMC_36310031","title":"A Regional and Projection-Specific Role of RGSz1 in the Ventrolateral Periaqueductal Grey in the Modulation of Morphine Reward.","date":"2022","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36310031","citation_count":8,"is_preprint":false},{"pmid":"15488170","id":"PMC_15488170","title":"Analysis of the regulation of microtubule dynamics by interaction of RGSZ1 (RGS20) with the neuronal stathmin, SCG10.","date":"2004","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/15488170","citation_count":8,"is_preprint":false},{"pmid":"37075876","id":"PMC_37075876","title":"Palmitoylation of RGS20 affects Gαo-mediated signaling independent of its GAP activity.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/37075876","citation_count":6,"is_preprint":false},{"pmid":"15488169","id":"PMC_15488169","title":"Analysis of RGSZ1 protein interaction with Galphai subunits.","date":"2004","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/15488169","citation_count":2,"is_preprint":false},{"pmid":"41315804","id":"PMC_41315804","title":"RGS20 reduces glioma stemness and temozolomide resistance by intrinsically inhibiting the WNT/β-catenin signaling pathway.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41315804","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13661,"output_tokens":5131,"usd":0.058974,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13376,"output_tokens":4596,"usd":0.09089,"stage2_stop_reason":"end_turn"},"total_usd":0.149864,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"RGSZ1 (RGS20) is a Gz-selective GTPase-activating protein (GAP) that accelerates hydrolysis of Gαz-GTP over 400-fold with Km ~2 nM, shows 100-fold selectivity for Gαz over Gαi, and when co-reconstituted into phospholipid vesicles with Gz and m2 muscarinic receptors increased agonist-stimulated GTPase >15-fold. RGSZ1 is tightly membrane-bound in brain and its regulatory activity depends on stable bilayer association.\",\n      \"method\": \"In vitro GTPase assay with purified recombinant protein, phospholipid vesicle reconstitution, membrane fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified components, multiple orthogonal assays, replicated across two simultaneous papers (PMIDs 9748280 and 9748279)\",\n      \"pmids\": [\"9748280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Phosphorylation of Gαz by protein kinase C (PKC) inhibits the GAP activity of RGSZ1 (RGS20) toward Gαz-GTP, providing a mechanism for potentiation of Gz signaling by PKC.\",\n      \"method\": \"In vitro GTPase assay using PKC-phosphorylated Gαz and purified recombinant RGSZ1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic assay with defined substrates, independently reported in two simultaneous papers (PMIDs 9748280 and 9748279)\",\n      \"pmids\": [\"9748280\", \"9748279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RGSZ1 (RGS20) was identified via yeast two-hybrid as a binding partner for constitutively active Gαz, confirming selective interaction with Gαz over other Gαi family members.\",\n      \"method\": \"Yeast two-hybrid screen, biochemical GAP assay with recombinant protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — yeast two-hybrid plus in vitro enzymatic validation, replicated across two independent labs in the same year\",\n      \"pmids\": [\"9748279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RGSZ1 and Ret RGS are splice variants of a single gene, RGS20, which spans ~107 kb and contains at least seven exons. Multiple translational start sites within the RGSZ1 ORF may explain molecular weight heterogeneity of purified brain RGSZ protein.\",\n      \"method\": \"Genomic cloning, exon mapping, RT-PCR, Northern blot\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genomic characterization establishing gene structure, replicated across multiple tissue types\",\n      \"pmids\": [\"11735229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RGSZ1 (RGS20) interacts with Gαi subunits (not only Gαz) in an AlF4−-dependent manner and accelerates intrinsic GTPase activity of Gαi1. In PC12 cells, RGSZ1 blocks MAPK activity induced by α2-adrenergic receptor agonist, and attenuates D2 dopamine receptor agonist-induced SRE reporter activity in CHO cells.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, yeast two-hybrid with luciferase reporter, single-turnover GTPase assay, yeast pheromone response assay, MAPK assay, SRE reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (pull-down, co-IP, yeast two-hybrid, in vitro GTPase, functional cell assays) in a single study\",\n      \"pmids\": [\"12379657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RGSZ1 (RGS20) directly interacts with SCG10 (a microtubule-destabilizing protein) via yeast two-hybrid and direct binding assays. Upon NGF treatment, GFP-tagged RGSZ1 translocates to the Golgi complex in PC12 cells where SCG10 is also distributed. Binding of RGSZ1 to SCG10 blocks SCG10-induced microtubule disassembly in vitro.\",\n      \"method\": \"Yeast two-hybrid, direct binding assay, GFP live-cell imaging/subcellular localization, turbidimetric and microscopy-based in vitro microtubule polymerization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods including in vitro functional reconstitution and live-cell imaging with functional consequence\",\n      \"pmids\": [\"11882662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Knockdown of RGSZ1 (RGS20) with antisense oligodeoxynucleotides in mouse CNS significantly increased supraspinal antinociception by morphine, heroin, DAMGO, and endomorphin-1 (but not endomorphin-2), and extended morphine analgesia duration, while having no effect on delta opioid receptor agonists DPDPE and deltorphin II. RGSZ1 knockdown facilitated morphine tolerance development.\",\n      \"method\": \"Antisense oligodeoxynucleotide knockdown in vivo, antinociception behavioral assay\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vivo knockdown with specific behavioral phenotype, but single lab, single primary method\",\n      \"pmids\": [\"14997173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RGSZ1 (RGS20) interacts with PKCI-1 via its N-terminal cysteine string region (shared with RZ subfamily), confirmed by co-immunoprecipitation and immunofluorescence. RGSZ1 and PKCI-1 together significantly reduce mu opioid receptor-mediated inhibition of cAMP more than RGSZ1 alone. 14-3-3 inhibits PKC-mediated phosphorylation of Gαz, and RGSZ1 competes with PKCI-1 for 14-3-3 binding.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence, cAMP functional assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — yeast two-hybrid plus co-IP plus functional cAMP assay, single lab\",\n      \"pmids\": [\"17126529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Activated Gαo and Gαi2 (but not Gαq, Gαi1, or Gαi3) interact with RGS20 and promote its proteasomal degradation via ubiquitination. Serotonin-1A receptor activation reduces RGS20 levels through this Gαo/i-proteasomal mechanism. Loss of RGS20 via this pathway reduces RGS20-mediated attenuation of Gi inhibition of β-adrenergic receptor-induced cAMP, enabling cross-pathway signal integration.\",\n      \"method\": \"Co-immunoprecipitation, proteasomal inhibitor (lactacystin, MG132) rescue experiments, ubiquitination assay, cAMP functional assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional and biochemical assays in single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18407463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RGS20 forms a ternary pre-associated complex with the melatonin MT1 receptor dimer and Gi protein. BRET analysis with probes at multiple sites revealed an asymmetric architecture in which one Gi and one RGS20 bind to separate protomers of the MT1 dimer; this complex rearranges upon agonist activation. Validated with MT1/MT2 heterodimers.\",\n      \"method\": \"Bioluminescence resonance energy transfer (BRET) with multi-site probe insertion, validated with heterodimers\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — BRET with multiple probe positions providing structural constraints, cross-validated with receptor heterodimers, rigorous single study\",\n      \"pmids\": [\"20859254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Estradiol benzoate treatment increases a 55 kDa membrane-associated RGSZ1 (RGS20) protein in the paraventricular nucleus of the hypothalamus and other brain regions, associated with partial desensitization of 5-HT1A receptor signaling as measured by reduced oxytocin and ACTH release.\",\n      \"method\": \"Western blotting, subcellular fractionation, in vivo hormone release assay\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — biochemical fractionation with in vivo functional readout, single lab\",\n      \"pmids\": [\"22251927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 stimulation alters post-translational modifications of RGSz1 (RGS20): high-molecular-weight RGSz1 isoforms are SUMOylated and glycosylated, localize to detergent-resistant membrane microdomains (DRM), and are increased by estradiol and G-1 treatment. Activated Gαz also localizes to DRM, so increased DRM-localized RGSz1 is proposed to reduce Gαz activity and functionally uncouple 5-HT1AR signaling.\",\n      \"method\": \"Subcellular fractionation (DRM isolation), immunoblotting for SUMOylation/glycosylation/phosphorylation, in vivo hormone release functional assay\",\n      \"journal\": \"Neuroendocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — biochemical fractionation plus PTM characterization with in vivo functional readout, single lab\",\n      \"pmids\": [\"25402859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Chronic morphine administration promotes RGSz1 (RGS20) activity in the periaqueductal gray (PAG), which modulates Wnt/β-catenin transcriptional signaling to promote analgesic tolerance. Suppression of RGSz1 stabilizes Axin2-Gαz complexes near the membrane and promotes β-catenin activation, delaying morphine tolerance.\",\n      \"method\": \"Genetic mouse models (global and brain region-targeted RGSz1 knockout/knockdown), biochemical assays, next-generation RNA sequencing, viral vector delivery\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models with region-specific manipulation, biochemical pathway analysis, transcriptomics, replicated across sex\",\n      \"pmids\": [\"29440403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RGS20 interacts physically with the PI3K p85α subunit in penile cancer cell lines and regulates PI3K/AKT signaling activation. Knockdown of PI3K p85α or p110α phenocopies RGS20 depletion, while expression of constitutively active PI3K p110α rescues proliferation and migration defects caused by RGS20 depletion.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, constitutively active PI3K overexpression rescue, xenograft tumor model\",\n      \"journal\": \"Journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — co-IP plus epistasis via rescue experiment, in vitro and in vivo, single lab\",\n      \"pmids\": [\"35498542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RGSz1 (RGS20) in vlPAG projections to the VTA modulates morphine reward. BRET sensor experiments demonstrate RGSz1 selectively modulates Gαz (but not other Gαi family subunits) and impedes MOPR-mediated Gαz signaling; RGSz1 KO enhances opioid-induced cAMP inhibition in PAG membranes.\",\n      \"method\": \"Cre-dependent viral vector knockdown in specific brain circuits, conditioned place preference assay, BRET sensors, cAMP inhibition assay in PAG membranes\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — circuit-specific genetic manipulation plus BRET-based biochemical selectivity assay plus functional cAMP readout, multiple orthogonal approaches\",\n      \"pmids\": [\"36310031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RGS20 is palmitoylated, and a conserved cysteine residue in the RGS domain is a critical palmitoylation site. Palmitoylation increases RGS20 association with active Gαo but does not affect GAP activity per se; however, palmitoylation increases inhibition of Gαo-mediated cAMP signaling, indicating a non-GAP mechanism of Gαo regulation by RGS20.\",\n      \"method\": \"Palmitoylation assay, site-directed mutagenesis of cysteine residues, co-immunoprecipitation with active Gαo, cAMP functional assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis plus biochemical binding plus functional cAMP assay, single lab\",\n      \"pmids\": [\"37075876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SP1 undergoes phase separation and activates RGS20 transcription through super-enhancer (SE) mechanisms. CUT&RUN identified RGS20 as the top SP1/H3K27ac SE target in lung adenocarcinoma; SP1 zinc finger 3 in the DNA-binding domain is essential for phase separation. The demethylase inhibitor GSK-J4 abolishes SP1 phase separation and RGS20 activation.\",\n      \"method\": \"CUT&RUN (SP1 and H3K27ac), phase separation assay, domain deletion mutagenesis, GSK-J4 inhibitor treatment, reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CUT&RUN plus functional phase separation assay plus mutagenesis, single lab\",\n      \"pmids\": [\"38976739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RGS20 promotes NSCLC cell proliferation by inhibiting PKA-Hippo signaling, reducing YAP phosphorylation and facilitating its nuclear translocation, and by activating autophagy. Forskolin (a GPCR/PKA activator) increased YAP phosphorylation and reversed the proliferative effect of RGS20 overexpression.\",\n      \"method\": \"Transcriptome sequencing, immunofluorescence for YAP nuclear translocation, Western blotting, Hippo pathway inhibitor (GA-017), PKA activator (forskolin) rescue, in vivo xenograft\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — transcriptomics plus imaging plus pharmacological rescue in vitro and in vivo, single lab\",\n      \"pmids\": [\"38431606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RGS20 inhibition in glioma cells intrinsically activates WNT/β-catenin signaling in a ligand-independent manner, enhancing tumor sphere formation, upregulating stem cell markers, and promoting temozolomide resistance. This mechanism operates in hypoxic niches where β-catenin signaling is enriched with low RGS20 expression.\",\n      \"method\": \"In vitro sphere formation, stem cell marker expression, in vivo tumor model, human glioblastoma specimen analysis, RGS20 knockdown/overexpression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — loss-of-function with specific pathway and phenotypic readout in vitro and in vivo, single lab, no biochemical mechanism of how RGS20 inhibits β-catenin established\",\n      \"pmids\": [\"41315804\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RGS20 (RGSZ1/ZGAP1) is a member of the RZ subfamily of RGS proteins that primarily functions as a highly selective GTPase-activating protein (GAP) for Gαz (and to a lesser extent Gαi/o), accelerating Gαz-GTP hydrolysis >400-fold; its activity is regulated by PKC-mediated phosphorylation of Gαz (which inhibits GAP activity), by palmitoylation of a conserved RGS-domain cysteine (which enhances Gαo association and inhibition independent of GAP activity), and by Gαo/i-stimulated ubiquitination and proteasomal degradation; it localizes to membranes and Golgi through a cysteine string motif and interacts with partners including PKCI-1, SCG10/stathmin (blocking microtubule disassembly), and the PI3K p85α subunit; within GPCR signaling complexes it occupies a distinct protomer of receptor dimers (e.g., MT1) from the coupled G protein; in the brain it modulates mu opioid receptor signaling and morphine tolerance via Gαz/Wnt/β-catenin cross-talk in the periaqueductal gray, and in cancer contexts it regulates PI3K/AKT and PKA-Hippo-YAP pathways and WNT/β-catenin signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RGS20 (RGSZ1) is a membrane-bound GTPase-activating protein of the RZ subfamily of RGS proteins that functions as a highly selective negative regulator of Gz-coupled G protein signaling [#0, #2]. It accelerates hydrolysis of Gαz-GTP over 400-fold with ~100-fold selectivity for Gαz over Gαi, and its regulatory activity depends on stable bilayer association [#0]; RGSZ1 and Ret RGS arise as splice variants of the single RGS20 gene [#3]. Although Gz-selective, RGS20 also engages Gαi subunits in an activation-dependent manner and dampens receptor-driven MAPK and SRE signaling [#4]. RGS20 activity is tuned by multiple inputs: PKC phosphorylation of Gαz inhibits its GAP activity [#1], palmitoylation of a conserved RGS-domain cysteine enhances association with active Gαo and inhibition of Gαo-cAMP signaling through a non-GAP mechanism [#15], and activated Gαo/Gαi2 promote RGS20 ubiquitination and proteasomal degradation, allowing receptor-driven cross-pathway signal integration [#8]. Within GPCR complexes, RGS20 pre-associates with melatonin MT1 receptor dimers and Gi in an asymmetric architecture, occupying a separate protomer from the coupled G protein [#9]. In the CNS, RGS20 constrains mu opioid receptor signaling and morphine antinociception, and chronic morphine drives RGSz1 activity in the periaqueductal gray to promote analgesic tolerance via Gαz/Axin2/Wnt–β-catenin cross-talk, while circuit-specific RGSz1 in vlPAG-to-VTA projections modulates opioid reward [#6, #12, #14]. In cancer, RGS20 acts as a proliferative driver through physical interaction with the PI3K p85α subunit and PI3K/AKT activation [#13], inhibition of PKA-Hippo signaling to promote YAP nuclear translocation [#17], and ligand-independent WNT/β-catenin activation supporting tumor stemness and drug resistance [#18]; its transcription is driven by SP1 super-enhancer phase separation [#16]. RGS20 additionally binds the microtubule-destabilizing protein SCG10 and blocks SCG10-induced microtubule disassembly [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the core biochemical identity of RGS20 as a Gz-selective GAP, answering what molecular activity this protein carries and on which G protein it acts.\",\n      \"evidence\": \"In vitro GTPase assays with purified protein, phospholipid vesicle reconstitution with Gz and m2 receptors, and yeast two-hybrid against constitutively active Gαz\",\n      \"pmids\": [\"9748280\", \"9748279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define structural basis of Gαz selectivity\", \"Cellular regulatory inputs not yet identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified the first regulatory input on RGS20 GAP activity, showing PKC phosphorylation of the Gαz substrate inhibits GAP function and thereby potentiates Gz signaling.\",\n      \"evidence\": \"In vitro GTPase assay using PKC-phosphorylated Gαz and purified recombinant RGSZ1\",\n      \"pmids\": [\"9748280\", \"9748279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation acts on substrate, not RGS20 directly\", \"In vivo relevance of this regulation not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the gene architecture, showing RGSZ1 and Ret RGS are splice variants of one RGS20 gene, explaining observed protein heterogeneity.\",\n      \"evidence\": \"Genomic cloning, exon mapping, RT-PCR and Northern blot across tissues\",\n      \"pmids\": [\"11735229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional distinction between isoforms not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Broadened the substrate and functional scope by showing RGS20 also acts on Gαi and attenuates receptor-driven MAPK/SRE signaling, and that it binds the microtubule-destabilizing protein SCG10.\",\n      \"evidence\": \"Pull-down, co-IP, yeast two-hybrid, single-turnover GTPase, cell-based MAPK/SRE reporters, and in vitro microtubule polymerization assays with Golgi localization imaging\",\n      \"pmids\": [\"12379657\", \"11882662\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of SCG10 binding in neurons not established\", \"Relative contribution of Gi versus Gz regulation in cells unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established a physiological role in opioid signaling, showing RGS20 constrains mu opioid receptor-mediated antinociception and modulates tolerance in vivo.\",\n      \"evidence\": \"Antisense oligodeoxynucleotide knockdown in mouse CNS with antinociception behavioral assays\",\n      \"pmids\": [\"14997173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab and single knockdown method\", \"Direct biochemical link to Gαz in this context not shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified protein partners (PKCI-1, 14-3-3) coupling RGS20 to the PKC/Gαz phosphorylation axis and showed enhanced suppression of MOPR-cAMP signaling.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, immunofluorescence, and cAMP functional assays\",\n      \"pmids\": [\"17126529\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Stoichiometry and direct structural basis of the competition for 14-3-3 not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined a feedback degradation mechanism in which activated Gαo/Gαi2 trigger RGS20 ubiquitination and proteasomal turnover, enabling cross-pathway signal integration.\",\n      \"evidence\": \"Co-IP, proteasome inhibitor rescue, ubiquitination assay, cAMP functional assay\",\n      \"pmids\": [\"18407463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase responsible for ubiquitination not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Provided structural insight into how RGS20 is organized within GPCR complexes, revealing an asymmetric pre-associated MT1 dimer-Gi-RGS20 architecture.\",\n      \"evidence\": \"BRET with multi-site probe insertion, cross-validated with MT1/MT2 heterodimers\",\n      \"pmids\": [\"20859254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure\", \"Generality across other receptor dimers not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked hormone/estrogen signaling to RGS20 regulation via post-translational modification and membrane microdomain targeting controlling 5-HT1A receptor signaling.\",\n      \"evidence\": \"DRM fractionation, immunoblotting for SUMOylation/glycosylation, and in vivo hormone release assays (also building on 2012 estradiol findings)\",\n      \"pmids\": [\"25402859\", \"22251927\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymes mediating SUMOylation/glycosylation not identified\", \"Causal link between DRM localization and Gαz inactivation inferred\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established the in vivo circuit and transcriptional mechanism by which RGS20 controls morphine tolerance through Gαz/Axin2/Wnt-β-catenin cross-talk in the periaqueductal gray.\",\n      \"evidence\": \"Global and region-targeted RGSz1 mouse models, biochemical assays, RNA-seq, and viral delivery\",\n      \"pmids\": [\"29440403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of Axin2-Gαz complex stabilization incomplete\", \"Direct GAP-versus-scaffold contribution not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended circuit-level and biochemical selectivity findings, confirming RGSz1 selectively impedes MOPR-mediated Gαz signaling and modulates opioid reward.\",\n      \"evidence\": \"Cre-dependent circuit-specific viral knockdown, conditioned place preference, BRET sensors, and PAG membrane cAMP assays\",\n      \"pmids\": [\"36310031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors in VTA projection not fully mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered palmitoylation of a conserved RGS-domain cysteine as a GAP-independent regulatory mechanism enhancing Gαo association and inhibition.\",\n      \"evidence\": \"Palmitoylation assay, cysteine mutagenesis, co-IP with active Gαo, and cAMP functional assays\",\n      \"pmids\": [\"37075876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Palmitoyltransferase responsible not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established RGS20 as a cancer driver and defined its transcriptional control, linking SP1 super-enhancer phase separation to RGS20 expression and RGS20 to PI3K/AKT and PKA-Hippo-YAP signaling.\",\n      \"evidence\": \"CUT&RUN, phase separation and reporter assays, co-IP with PI3K p85α, epistasis rescue, transcriptomics, and xenograft models (also penile cancer p85α study)\",\n      \"pmids\": [\"38976739\", \"38431606\", \"35498542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between RGS20 GAP/G-protein activity and PI3K or Hippo regulation unresolved\", \"Single lab per cancer context\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected RGS20 loss to ligand-independent WNT/β-catenin activation driving glioma stemness and drug resistance in hypoxic niches.\",\n      \"evidence\": \"Sphere formation, stem marker expression, knockdown/overexpression, in vivo tumor model, and human glioblastoma specimens\",\n      \"pmids\": [\"41315804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No biochemical mechanism for how RGS20 represses β-catenin established\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how RGS20's defined Gαz/Gαi GAP and palmitoylation-dependent activities mechanistically connect to the PI3K/AKT, PKA-Hippo-YAP, and WNT/β-catenin pathways it controls in cancer, and which E3 ligase and modifying enzymes govern its turnover and PTMs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of RGS20 in GPCR complexes at atomic resolution\", \"Direct biochemical bridge between G-protein regulation and oncogenic signaling pathways missing\", \"Enzymes mediating ubiquitination, SUMOylation, glycosylation, and palmitoylation unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 4, 15]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 11, 15]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 8, 9]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [6, 12, 14]}\n    ],\n    \"complexes\": [\n      \"MT1 receptor dimer–Gi–RGS20 ternary complex\"\n    ],\n    \"partners\": [\n      \"GNAZ\",\n      \"GNAO1\",\n      \"GNAI2\",\n      \"SCG10/STMN2\",\n      \"HINT1/PKCI-1\",\n      \"YWHA/14-3-3\",\n      \"PIK3R1/p85α\",\n      \"MTNR1A/MT1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}